Filing Flows › PTC Therapeutics (PTCT) › Q2 2026 › vs Q2 2025
PTC Therapeutics (PTCT) Q2 2026 vs Q2 2025 (year over year)
PTC Therapeutics's revenue rose $182M (+102%) from $179M in Q2 2025 to $361M in Q2 2026. The biggest changes: Collaboration and license revenue +$47.7M (17×); Royalty revenue +$13.5M (+23%). Operating margin 41.3% against -19.5% (+60.9 pts).
PTC Therapeutics, Q2 2026: revenue $361M (+102% year over year), operating margin 41.3%, net earnings $83.5M, operating cash flow $129M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 41.3% | -19.5% | +60.9 pts |
| Net margin | 23.2% | -36.3% | +59.4 pts |
| Free cash flow margin | 35.2% | -33.3% | +68.5 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Translarna | $42.2M | $59.5M | −$17.3M | -29% |
| Emflaza | $24.6M | $36.4M | −$11.7M | -32% |
| Upstaza/Kebilidi | $11.2M | $11.9M | −$726K | -6% |
| All other products | $9.5M | $10.6M | −$1.1M | -11% |
| Royalty revenue | $71.1M | $57.6M | $13.5M | +23% |
| Collaboration and license revenue | $50.6M | $2.9M | $47.7M | 17× |
| Revenue | $361M | $179M | $182M | +102% |
| Operating profit | $149M | −$35.0M | $184M | — |
| Costs & expenses | $212M | $214M | −$2.3M | -1% |
| Pre-tax earnings | $97.5M | −$71.1M | $169M | — |
| Other expense, net | $51.4M | $36.1M | $15.3M | +42% |
| Research & development | $99.2M | $113M | −$13.8M | -12% |
| SG&A | $80.6M | $85.3M | −$4.6M | -5% |
| Other operating costs | $31.8M | $15.6M | $16.2M | +104% |
| Net earnings | $83.5M | −$64.8M | $148M | — |
| Income tax | $14.0M | −$6.2M | $20.3M | — |
| Depreciation & amortization | $15.9M | $7.6M | $8.3M | +109% |
| Share-based compensation | $23.3M | $18.5M | $4.7M | +26% |
| Working capital & other | $6.5M | −$19.6M | $26.1M | — |
| Operating cash flow | $129M | −$58.3M | $187M | — |
| Free cash flow (OCF − capex) | $127M | −$59.6M | $187M | — |
| Capital expenditures | $2.2M | $1.2M | $945K | +76% |
Questions
How much did PTC Therapeutics's revenue grow year over year in Q2 2026?
PTC Therapeutics's revenue rose $182M (+102%) from $179M in Q2 2025 to $361M in Q2 2026.
What drove PTC Therapeutics's revenue change in Q2 2026?
Collaboration and license revenue +$47.7M (17×); Royalty revenue +$13.5M (+23%).